These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 2993671)

  • 1. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases.
    Logothetis CJ; Samuels ML; Ogden S; Dexeus FH; Swanson D; Johnson DE; von Eschenbach A
    J Urol; 1985 Sep; 134(3):460-4. PubMed ID: 2993671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience.
    Logothetis CJ; Dexeus FH; Chong C; Sella A; Ayala AG; Ro JY; Pilat S
    J Urol; 1989 Jan; 141(1):33-7. PubMed ID: 2908950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors.
    Logothetis CJ; Samuels ML; Selig DE; Wallace S; Johnson DE
    Cancer Treat Rep; 1985 Jan; 69(1):33-8. PubMed ID: 2981619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N; Weiselberg LR
    J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of chemotherapy in advanced urothelial carcinoma: with special reference to combination chemotherapy with adriamycin, cyclophosphamide and cisplatin (ACE chemotherapy)].
    Tobisu K; Matsumoto K; Takai K; Kakizoe T
    Nihon Hinyokika Gakkai Zasshi; 1987 Feb; 78(2):327-34. PubMed ID: 3613336
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant intra-arterial chemotherapy in the treatment of advanced transitional cell carcinoma of the bladder: results and followup.
    Galetti TP; Pontes JE; Montie J; Medendorp SV; Bukowski R
    J Urol; 1989 Nov; 142(5):1211-4; discussion 1214-5. PubMed ID: 2810495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial.
    Troner M; Birch R; Omura GA; Williams S
    J Urol; 1987 Apr; 137(4):660-2. PubMed ID: 3550148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination chemotherapy with methotrexate (MTX), vincristine (VCR), cisplatinum (CDDP), cyclophosphamide (CPM), adriamycin (ADM), and bleomycin (BLM); MVP-CAB in patients with advanced urothelial tract cancer].
    Fujii A; Morishita S; Nakamura I; Oka Y; Ohshima H; Nagata H; Iwamoto T; Izumi T; Miyasaki Z; Ito N
    Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):985-93. PubMed ID: 2460657
    [No Abstract]   [Full Text] [Related]  

  • 11. Intra-arterial chemotherapy as an adjuvant to surgery in transitional cell carcinoma of the bladder.
    Maatman TJ; Montie JE; Bukowski RM; Risius B; Geisinger M
    J Urol; 1986 Feb; 135(2):256-60. PubMed ID: 3944856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.
    Scher HI; Yagoda A; Herr HW; Sternberg CN; Bosl G; Morse MJ; Sogani PC; Watson RC; Dershaw DD; Reuter V
    J Urol; 1988 Mar; 139(3):470-4. PubMed ID: 3343728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.
    Maru A; Akaza H; Isaka S; Koiso K; Kotake T; Machida T; Matsumura Y; Nakagami Y; Niijima T; Obata K
    Cancer Chemother Pharmacol; 1987; 20 Suppl():S44-8. PubMed ID: 3311445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens.
    Dexeus FH; Logothetis CJ; Samuels ML; Ayala AG; Hossan E
    J Urol; 1987 Jan; 137(1):122-5. PubMed ID: 3795354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience.
    Tannock I; Gospodarowicz M; Connolly J; Jewett M
    J Urol; 1989 Aug; 142(2 Pt 1):289-92. PubMed ID: 2746745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.
    Campbell M; Baker LH; Opipari M; Al-Sarraf M
    Cancer Treat Rep; 1981; 65(9-10):897-9. PubMed ID: 7196800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer.
    Ueki O; Hisazumi H; Uchibayashi T; Naito K; Tajiri S; Takemae K; Kawaguchi K; Kameda K; Nishino A; Nango C
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S72-6. PubMed ID: 1394823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.